Dec 24, 2020 — 4 min read
A study conducted by Seoul National University Hospital, one of the most renowned medical institutes in Asia, has revealed that an AI can help radiologists improve their performance and reduce reporting time for critical or urgent cases. The study has recently been published in European Respiratory Journal, one of the leading peer-reviewed journals for respiratory diseases.
According to the study, Lunit INSIGHT CXR, an AI software for chest x-ray, showed significant value in a simulated reading experiment for emergency patients. When assisted by Lunit’s AI, the diagnostic accuracy more than doubled from 29.2% to 70.8% for critical-emergency diseases such as pneumothorax and pneumoperitoneum.
In addition, by analyzing abnormal findings in advance and triaging the images for urgent diagnosis, the waiting time of emergency patients has been drastically reduced by 80%. The overall reading time has also shortened, leading to reading efficiency and dramatic improvement of patient treatment in emergency situations.
“This study actually shows that reading efficiency can be maximized when the radiologists and AI system are organically integrated,” said Professor Chang-min Park, the corresponding author of the study. “It especially shows high value in emergency cases where timely diagnosis and care is required for patients."
Brandon Suh, CEO of Lunit said, “It is meaningful that our AI is recognized and validated for more sophisticated and quick diagnosis of chest diseases. Continuous development of our algorithm shall be implemented to reduce the heavy workloads of radiologists and emergency personnels.”
The study further emphasized that Lunit INSIGHT CXR can detect 10 diseases (lung cancer, pulmonary nodules, atelectasis, calcification, cardiomegaly, consolidation, fibrosis, pleural effusion, pneumoperitoneum, and pneumothorax) on chest x-ray images. In fact, most lung and chest diseases can be diagnosed through this AI solution.
Using two external validation datasets of same-day CT-confirmed and open-source datasets, Lunit INSIGHT CXR showed diagnostic ability comparable to that of a radiologist. It resulted in high AUROCs for all 10 common abnormalities, ranging from 0.9-1.00. AUROC value of 1.00 implies the highest performance.
Professor Joo-gang Nam, the first author of the study stated “Lunit INSIGHT CXR individually marks the location and probability of abnormal findings for each of the 10 lesions. This is a technology that was not implemented in the previous generation of artificial intelligence, which opens the way for automatic detection and diagnosis.”
Lunit INSIGHT CXR clinically analyzed more than 6.5 million images in more than 80 countries. It is CE marked and clinically available in Europe, Middle East, Latin America, South East Asia, Australia, and New Zealand. It is expecting its FDA clearance within early 2021.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis